Home / Market News / $VTGN
fiscal.ai Corporate Catalyst Impact 75/100 ● neutral

Vistagen Reports Fiscal Year 2027 Second Quarter Financial Results

Nov 15, 2026, 2:07 PM UTC · Primary ticker $VTGN

Vistagen reported a net loss of $10.7 million for Q2 FY27, with R&D and G&A expenses totaling $11.1 million. The company's cash position of $20.0 million is projected to fund operations into 2027, but not for more than a year, indicating potential future financing needs.

Vistagen Therapeutics announced its Q2 FY27 financial results, reporting a net loss of $10.7 million and R&D expenses of $6.6 million. The company's cash balance of $20.0 million is only sufficient to fund operations into 2027, implying a cash runway of less than a year from the reporting date. This is significant for VTGN as it highlights ongoing cash burn and the potential need for future capital raises, which could dilute existing shareholders. Short-term, this could put downward pressure on the stock due to concerns about liquidity and future dilution. Long-term, the company's ability to secure additional funding and advance its pipeline will be critical. The key risk for traders is the impending need for financing, which could lead to stock price volatility.

$VTGN negative Reported net loss and limited cash runway
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.